Key Insights• The South Africa biosurgery market represents the largest and most established national market for surgical biomaterials in Sub-Saharan Africa. Valued at more than USD 98 million in 2025, the market is expected to reach a market size of more than USD 66 million by 2031. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The South Africa biosurgery market is distinguished by its dual healthcare system, comprising a well-resourced private sector and an overstretched public sector serving the majority of the population. According to Statistics South Africa (Stats SA), the country's mid-year population is estimated at 63.10 million in 2025. Health spending reached approximately 9.14% of GDP in 2025, ranking 40th globally and representing an all-time high. Health spending overall is expected to grow from 277 billion rand in 2024/25 to 329 billion rand in 2027/28.

The market is shaped by a complex interplay of demographic trends, the implementation of National Health Insurance (NHI), regulatory modernization through SAHPRA, and the growing adoption of advanced surgical technologies.• Bone-Graft Substitutes represent the largest product category within the South African biosurgery market, driven by the high volume of orthopedic and trauma procedures. The country's growing elderly population with 4.46 million people (approximately 7.1% of the population) aged 65 years or older in 2025 continues to drive demand for musculoskeletal interventions. Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive and robotic surgical techniques. Universitas Academic Hospital in Bloemfontein launched the advanced Versius Robotic Surgery System in partnership with the Free State Health Department.• South Africa's aging population represents a significant long-term demand driver. The population aged 65 and older has grown from 526,381 in 1953 to 4.46 million in 2025, an 8.4-fold increase. The number of people aged 60 and above has risen from 3.6 million in 2002 to 6.6 million in 2025.The regulatory environment, centered on the South African Health Products Regulatory Authority (SAHPRA), plays a decisive role in shaping market dynamics.

Medical devices are classified into four risk tiers (Class A, B, C, and D), and manufacturers must obtain an establishment license before selling products in SouthMarket Outlook• According to the research report, "South Africa Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the South Africa Biosurgery market is expected to reach a market size of more than USD 66 Million by 2031.• The South African biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, expanding surgical volumes, and the implementation of the National Health Insurance (NHI) framework. South Africa's healthcare expenditure continues to rise, reaching 9.14% of GDP in 2025, the highest on record. Health spending is expected to grow from 277 billion rand in 2024/25 to 329 billion rand in 2027/28. An additional 28.9 billion rand ($1.5 billion) was earmarked for health spending in the 2025 budget. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization.• The aging South African population represents the most significant long-term demand driver. As of 2025, 4.46 million people (approximately 7.1% of the population) were aged 65 years or older.

The number of people aged 60 and above has risen from 3.6 million in 2002 to 6.6 million in 2025. Life expectancy at birth has improved to 64 years for males and 69 years for females in 2025. This demographic shift will drive increased demand for orthopedic, cardiovascular, and other surgical interventions. Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Universitas Academic Hospital in Bloemfontein launched the advanced Versius Robotic Surgery System. Tygerberg Hospital performed South Africa's first fully internal bone transport and limb-lengthening reconstruction in December 2025.

Charlotte Maxeke Johannesburg Academic Hospital became the first health facility in Gauteng to perform MitraClip implants in February 2025.• Expanding surgical access and the NHI implementation are key drivers. The National Health Insurance Act, signed into law in May 2024, aims to ensure all South Africans receive the same quality of care, regardless of income. The National Department of Health Strategic Plan 2025–2030 is anchored in the implementation of the NHI. While full implementation could take up to 15 years, the NHI framework will drive increased surgical volumes and healthcare access across the public sector.Market DynamicsDriver: Expanding Healthcare Infrastructure and Surgical CapacitySouth Africa possesses the largest healthcare infrastructure in Sub-Saharan Africa, with over 470 public hospitals, over 260 private hospitals, over 3,000 public clinics, and over 1,500 private clinics. The government has announced plans to build six new academic hospitals across the country to address ongoing challenges in the healthcare sector. In 2025, the National Health Council approved the procurement of 1.4 million hospital items, including 25,000 specialised hospital beds at a cost of R725 million.

Gauteng has the most healthcare facilities due to its large population and major economic activity. Surgical capacity is also expanding through public-private partnerships, with the Health Department planning to appoint 1,200 additional doctors in 2025. These infrastructure investments directly drive demand for biosurgical products across all categories.Challenge: Healthcare Workforce Constraints and Infrastructure GapsDespite significant healthcare investment, South Africa faces persistent challenges that limit the full potential of the biosurgery market. Only the Western Cape meets the minimum threshold of 20 surgical specialists per 100,000 population required for safe surgery. At least 1,800 junior doctors who completed community service were left unemployed at the start of 2025 due to budget cuts. The public healthcare system serves 85% of the population but is overstretched and underfunded.

Hospital bed density stands at 2.25 beds per 1,000 population in 2025. While the government has approved the procurement of 25,000 new beds, significant infrastructure gaps persist. These workforce and infrastructure constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics in the public sector.Trend: Accelerating Adoption of Robotic-Assisted and Minimally Invasive SurgeryThe South African biosurgery market is experiencing a significant trend toward robotic-assisted and minimally invasive surgical techniques. Universitas Academic Hospital in Bloemfontein launched the advanced Versius Robotic Surgery System in partnership with the Free State Health Department and the University of the Free State. Tygerberg Hospital performed South Africa's first fully internal bone transport and limb-lengthening reconstruction in December 2025, allowing surgeons to complete both bone transport and subsequent limb lengthening without external frames. Charlotte Maxeke Johannesburg Academic Hospital became the first health facility in Gauteng to perform MitraClip implants in February 2025.

This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand.Policies• The South African Health Products Regulatory Authority (SAHPRA), a division of the National Department of Health, regulates medical devices in South Africa under the Medicines and Related Substances Act, 1965 (Act 101 of 1965).• Medical devices are classified into four risk tiers: Class A, B, C, and D. Classification is determined by a rule-based system that includes 16 rules in the Guideline for Classification of Medical Devices and IVDs.• Manufacturers must obtain an establishment license before selling products in South Africa. Class C and D devices must provide proof of market authorization in an approved reference market, including Australia, Brazil, Canada, Japan, European Union, or United States.• Quality Management System (QMS) requirements took effect on June 1, 2025. Manufacturers applying for a new or renewal Medical Device Establishment License must submit a valid ISO 13485:2016 certificate from a SAHPRA-recognized CAB.• Foreign manufacturers must retain an Authorized Representative (AR) based in South Africa, who serves as the liaison to SAHPRA and ensures compliance with local laws and guidelines.• The National Health Insurance (NHI) Act, signed into law in May 2024, aims to achieve universal health coverage. The NHI is being implemented in two phases: Phase 1 from 2023 to 2026 and Phase 2 from 2026 to 2028.

The 2025/26 budget includes incremental VAT increases to help finance the NHI.Segment AnalysisSouth Africa Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the South African biosurgery market, driven by the high volume of orthopedic and trauma procedures. South Africa's growing elderly population with 4.46 million people aged 65 and older and 6.6 million aged 60 and above continues to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. Orthopedic surgery in South Africa includes joint replacements, spinal fusions, and complex trauma procedures such as the first fully internal limb reconstruction performed at Tygerberg Hospital. Waiting times for orthopedic procedures remain substantial, with arthroplasty waiting times reaching up to 5 years in some provinces, creating significant pent-up demand.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding.

South Africa's extensive hospital network, with over 730 hospitals and thousands of clinics across the public and private sectors, ensures consistent demand for hemostatic products. The expansion of surgical marathons, including initiatives for prostate, cleft palate, cataract, and stoma procedures, further drives demand for hemostatic agents.• Surgical Sealants and Adhesives represent the fastest-growing product category in the South African biosurgery market, driven by increasing adoption of robotic-assisted and minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The launch of the Versius Robotic Surgery System at Universitas Academic Hospital and the adoption of advanced procedures such as MitraClip implants support the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in South African hospitals.

General surgeons in South Africa most frequently perform hernia repair (95%), appendicectomy (91%), emergency laparotomy (88%), and laparoscopic cholecystectomy (80%).• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. The increasing volume of thoracic and gastrointestinal procedures, including the growing adoption of minimally invasive techniques, supports steady demand for these products.South Africa Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in South Africa, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures. Orthopedic procedures include femur fracture repairs (4-month average waiting time) and arthroplasty (5-year waiting time). The aging population with 4.46 million people aged 65 and older and 6.6 million aged 60 and above continues to drive demand for musculoskeletal interventions. Tygerberg Hospital's first fully internal bone transport and limb-lengthening reconstruction in 2025 reflects ongoing innovation in this specialty.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures. The 10 most frequently listed procedures by South African-trained general surgeons are hernia repair (95%), appendicectomy (91%), emergency laparotomy (88%), laparoscopic cholecystectomy (80%), gastroscopy (80%), and colonoscopy (61%).

Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. Surgical marathons in Gauteng hospitals have included breast surgeries, hernia repairs, and colostomy reversals.• Cardiovascular Surgery represents the fastest-growing application area in the South African biosurgery market, driven by the high prevalence of cardiovascular disease. Charlotte Maxeke Johannesburg Academic Hospital became the first health facility in Gauteng to perform MitraClip implants in February 2025. Cardiovascular diseases, along with cancer and diabetes, represent leading causes of morbidity in South Africa.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery. Gauteng Health hospitals have conducted surgical marathons including cleft palate and breast surgeries.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.

Uterine surgery procedures are routinely performed across South African hospitals.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications. Prostate procedures are included in surgical marathon initiatives.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.South Africa Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the South African biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. SAHPRA's rigorous requirements for medical devices ensure high safety standards for biological materials.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the South African market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. With over 90% of medical devices imported, synthetic products benefit from established global supply chains and competitive pricing.South Africa Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in South Africa, accounting for the majority of revenue.

The country has over 470 public hospitals and over 260 private hospitals. The public healthcare system serves 85% of the population. The government has announced plans to build six new academic hospitals. The concentration of complex surgical procedures makes hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the South African biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The country has over 1,500 private clinics, many of which function as day surgery facilities. The expansion of outpatient surgical capacity, supported by both public and private healthcare sectors, supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

South Africa has over 3,000 public clinics providing primary and some secondary care services.South Africa Biosurgery Market Economics• South Africa’s biosurgery market operates through a well-resourced private sector and an overstretched public healthcare system. Healthcare expenditure reached approximately 9.14% of GDP in 2025, with total health spending expected to rise from R277 billion in 2024/25 to R329 billion by 2027/28. Private hospitals serve around 15% of the population with medical insurance, while manufacturers must manage different pricing and procurement models across public and private sectors.• South Africa has the most extensive healthcare infrastructure in Sub-Saharan Africa, with more than 470 public and 260 private hospitals, alongside thousands of clinics. However, surgical workforce shortages remain significant, with only the Western Cape meeting recommended specialist thresholds. The country has approximately 6,670 surgeons, anesthesiologists, and obstetricians. Expansion of hospitals, procurement of medical equipment, and gradual implementation of the National Health Insurance (NHI) are expected to increase surgical capacity.• The market remains heavily dependent on imports, with more than 90% of medical devices sourced internationally.

The medical device market is projected to grow from approximately USD 1.12 billion in 2025 to USD 1.67 billion by 2032. Innovation is increasing through robotic surgery, minimally invasive procedures, and advanced biomaterials, demonstrated by the introduction of the Versius robotic system and complex reconstructive procedures at leading academic hospitals.• South Africa’s long-term biosurgery outlook is positive, supported by healthcare investment, technological advancement, ageing demographics, and NHI expansion. More than 4.46 million people are aged 65 or older, increasing demand for surgical care. SAHPRA remains central to medical device regulation, with ISO 13485:2016 quality requirements implemented from June 2025. The biosurgery market is expected to exceed USD 66 million by 2031, creating opportunities for manufacturers able to manage regulatory and procurement complexities.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.